

Press release from Emotra AB (publ)
Göteborg, May 3, 2017

Proposal to grant the Board of Directors the authority to decide on a new share issue for the market launch of EDOR®

The Board of Directors of Emotra AB (Emotra) is hereby serving notice for an extraordinary shareholder meeting to be held on May 19, 2017. This meeting is being held to vote on a resolution to grant the Board the authority to carry out a new share issue with right of priority for existing shareholders for a maximum of 20 MSEK. The goal of this authority is to strengthen the Company's working capital in anticipation of the market launch of its EDOR® method. The Board has also decided to postpone Emotra's regular annual shareholder meeting from June 13, 2017 to June 30, 2017.

Our clinical multi-centre study, EUDOR-A, which studied the ability of Emotra's method EDOR® to identify depressed patients at risk of committing suicide, was concluded on schedule in Q1 2017 with encouraging results. These results led to our consensus meeting, which was held in Rome on March 29–30, 2017 to evaluate our EDOR® study, supporting a market launch of EDOR®. In line with the recommendation from this consensus meeting, Emotra now plans to move on to a commercial market introduction. In accordance with our previously communicated goals and calculated capital needs, Emotra will need an injection of fresh working capital in order to be able to carry out our market launch of EDOR®.

In view of the planned market launch of EDOR® and the increased capital needs that these plans imply, the Board of Directors has decided to ask the extraordinary shareholder meeting being held on May 19, 2017 in Göteborg (see separate notice to be published soon) to grant the Board the authority to carry out a new share issue with right of priority for current shareholders in order to raise a maximum amount of 20 000 000 SEK.

Investor meetings

Claes Holmberg (CEO and board member of Emotra) and Lars-Håkan Thorell (board member of Emotra) will be presenting the Company's operations and future plans at Aktiespararnas investor meetings on May 8, 2017, in Göteborg, on May 15 in Stockholm and on May 23 in Malmö.

The Board has also decided to postpone Emotra's regular annual shareholder meeting from June 13, 2017 to June 30, 2017. A separate notice for the annual shareholder meeting will be published no later than four weeks before the meeting.

For further information about the Company, please contact:

Claes Holmberg, CEO
Telephone: +46 708 25 45 47
E-mail: claes@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on May 3, 2017 under the above contact's supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.